Tennessee Oncology Nashville / Sarah Cannon — Nashville, Tennessee

Tennessee Oncology Nashville / Sarah Cannon is a clinical research site located in Nashville, Tennessee, United States 37203.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Tennessee Oncology Nashville / Sarah Cannon has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer.

Sponsors: Daiichi Sankyo.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Nashville

Browse all research sites in Tennessee · View every site in Nashville

• Vanderbilt University Medical Center Diagnostic Lab- Site Number : 840049
• 10-20 Vanderbilt University Medical Center
• Monroe Carell Jr Children's Hospital at Vanderbilt
• Vanderbilt University Medical Center Clinical Research Center
• Vanderbilt University Medical Center /ID# 204231
• Vanderbilt University Medical Center-GCRC
• GI Clinical Research; Vanderbilt University Medical Center
• Vanderbilt University Medical Center /ID# 164607
• The Children's Hospital at TriStar Centennial Medical Center
• Vanderbilt University Medical Center; Multiple Sclerosis Center
• Monroe Carrell Jr Children's Hospital at Vanderbilt
• Vanderbilt University ASAP Research

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Tennessee Oncology Nashville / Sarah Cannon?

Tennessee Oncology Nashville / Sarah Cannon has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Tennessee Oncology Nashville / Sarah Cannon conducted?

Tennessee Oncology Nashville / Sarah Cannon has 1 clinical trials on record, with 1 currently active. Their work covers HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer.

Is Tennessee Oncology Nashville / Sarah Cannon accredited by Crixeo Clinical Trials?

Tennessee Oncology Nashville / Sarah Cannon has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Tennessee Oncology Nashville / Sarah Cannon?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.